Literature DB >> 7104237

Decreased glycosylation of band 3 and band 4.5 glycoproteins of erythrocyte membrane in congenital dyserythropoietic anaemia type II.

P Scartezzini, G L Forni, M Baldi, C Izzo, G Sansone.   

Abstract

We report a study of HEMPAS erythrocyte membrane glycoproteins in relation to proteolytic digestion and surface labelling with galactose-oxidase/NaB[3H]4. The proteolytic digestion of band 3, the major intrinsic glycoprotein of the human erythrocyte membrane, reveals an abnormality in the outer glycosylated segment of this protein. 3H incorporation in band 3 and band 4.5 glycoproteins after treatment with galactose-oxidase/NaB[3H]4 is reduced in HEMPAS red cells suggesting a defective glycosylation of these proteins. These findings together with the persistence of i antigen and the normal presence of I antigen lead us to conclude that erythroblastic membrane features may persist in HEMPAS erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104237     DOI: 10.1111/j.1365-2141.1982.tb02820.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Incomplete synthesis of N-glycans in congenital dyserythropoietic anemia type II caused by a defect in the gene encoding alpha-mannosidase II.

Authors:  M N Fukuda; K A Masri; A Dell; L Luzzatto; K W Moremen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 2.  The congenital dyserythropoieitic anemias: genetics and pathophysiology.

Authors:  Richard King; Patrick J Gallagher; Rami Khoriaty
Journal:  Curr Opin Hematol       Date:  2021-12-24       Impact factor: 3.218

Review 3.  Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.

Authors:  T Marquardt; J Denecke
Journal:  Eur J Pediatr       Date:  2003-03-15       Impact factor: 3.183

4.  Characteristic phenotypes associated with congenital dyserythropoietic anemia (type II) manifest at different stages of erythropoiesis.

Authors:  Timothy J Satchwell; Stephanie Pellegrin; Paola Bianchi; Bethan R Hawley; Alexandra Gampel; Kathryn E Mordue; Annika Budnik; Elisa Fermo; Wilma Barcellini; David J Stephens; Emile van den Akker; Ashley M Toye
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941

Review 5.  The COPII pathway and hematologic disease.

Authors:  Rami Khoriaty; Matthew P Vasievich; David Ginsburg
Journal:  Blood       Date:  2012-05-14       Impact factor: 22.113

6.  SEC23A rescues SEC23B-deficient congenital dyserythropoietic anemia type II.

Authors:  Richard King; Zesen Lin; Ginette Balbin-Cuesta; Gregg Myers; Ann Friedman; Guojing Zhu; Beth McGee; Thomas L Saunders; Ryo Kurita; Yukio Nakamura; James Douglas Engel; Pavan Reddy; Rami Khoriaty
Journal:  Sci Adv       Date:  2021-11-24       Impact factor: 14.957

Review 7.  Clinical aspects and pathogenesis of congenital dyserythropoietic anemias: from morphology to molecular approach.

Authors:  Achille Iolascon; Maria Rosaria Esposito; Roberta Russo
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.